发布求助
文献互助 智能选刊 最新文献

The Journal of rheumatology. Supplement最新文献

筛选
英文 中文
Challenges in the Diagnosis and Assessment of Psoriatic Arthritis. 银屑病关节炎诊断与评估的挑战。
The Journal of rheumatology. Supplement Pub Date : 2022-04-15 DOI: 10.3899/jrheum.211337
A. Ogdie, C. Lindsay, P. Mease, K. Callis Duffin, C. Rosen, S. Siebert
{"title":"Challenges in the Diagnosis and Assessment of Psoriatic Arthritis.","authors":"A. Ogdie, C. Lindsay, P. Mease, K. Callis Duffin, C. Rosen, S. Siebert","doi":"10.3899/jrheum.211337","DOIUrl":"https://doi.org/10.3899/jrheum.211337","url":null,"abstract":"Each year, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) holds a trainee symposium adjacent to the GRAPPA annual meeting. The target audience for this meeting includes trainees in rheumatology, dermatology, and related fields. The 2021 GRAPPA Trainee Symposium focused on challenges in the diagnosis and assessment of psoriatic arthritis (PsA). During the meeting, speakers focused on identification of psoriasis (PsO), the differential diagnosis for both PsO and PsA, diagnostic errors and pitfalls, physical examination in PsA, patient-reported outcomes and composite measures in the assessment of PsA, and the patient perspective on diagnosis and assessment, followed by a panel discussion. This paper summarizes the content discussed at the meeting.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72412888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Whole-Body Macrophage Positron Emission Tomography Imaging for Disease Activity Assessment in Early Rheumatoid Arthritis 巨噬细胞正电子发射断层成像在早期类风湿关节炎疾病活动性评估中的应用
The Journal of rheumatology. Supplement Pub Date : 2022-04-15 DOI: 10.3899/jrheum.210928
N. Verweij, J. de Jongh, M. Wee, G. Zwezerijnen, M. Yaqub, A. Voskuyl, A. Lammertsma, D. van Schaardenburg, M. Boers, W. Lems, C. J. van der Laken
{"title":"Whole-Body Macrophage Positron Emission Tomography Imaging for Disease Activity Assessment in Early Rheumatoid Arthritis","authors":"N. Verweij, J. de Jongh, M. Wee, G. Zwezerijnen, M. Yaqub, A. Voskuyl, A. Lammertsma, D. van Schaardenburg, M. Boers, W. Lems, C. J. van der Laken","doi":"10.3899/jrheum.210928","DOIUrl":"https://doi.org/10.3899/jrheum.210928","url":null,"abstract":"Objective To investigate the potential of whole-body positron emission tomography/computed tomography (PET/CT) with a macrophage tracer to image arthritis in patients with early rheumatoid arthritis (RA). Methods Thirty-five previously untreated, clinically active patients with early RA underwent whole-body PET/CT scanning with the macrophage tracer (R)-[11C]PK11195 in addition to clinical assessment (Disease Activity Score in 44 joints [DAS44]). Tracer uptake was assessed quantitatively as standardized uptake values (SUVs). In addition, 2 readers blinded to clinical assessment visually scored tracer uptake in joints. Clinical and PET variables were compared using Cohen , linear regression/correlation, and t tests, where appropriate. Results All but 1 patient showed enhanced tracer uptake in at least 1 joint. Twelve percent of all joints (171/1470) were visually positive on the PET scan, most frequently the small joints in feet (40%) and hands (37%), followed by wrists (15%). Correlations of visual scores with clinical findings both at patient and joint levels were absent or weak. In contrast, average SUVs in the hands, feet, and whole body showed significant correlations with DAS44 scores, with the best correlation seen in the feet (R2 = 0.29, P < 0.01). Conclusion Clinically active patients with early RA had increased joint uptake of a macrophage PET tracer, especially in the feet. Quantitative, but not visual PET measures of whole body and joint groups, particularly the feet, showed moderate and statistically significant correlations with clinical outcome.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86123964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: Interim Report of Postmarketing Surveillance in Japan 他克莫司用于多肌炎或皮肌炎相关的间质性肺炎患者:日本上市后监测的中期报告
The Journal of rheumatology. Supplement Pub Date : 2022-04-15 DOI: 10.3899/jrheum.210322
M. Kuwana, N. Wakasugi, Toshinori Furuya, S. Uno, T. Suda
{"title":"Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: Interim Report of Postmarketing Surveillance in Japan","authors":"M. Kuwana, N. Wakasugi, Toshinori Furuya, S. Uno, T. Suda","doi":"10.3899/jrheum.210322","DOIUrl":"https://doi.org/10.3899/jrheum.210322","url":null,"abstract":"Objective. The calcineurin inhibitor tacrolimus has been approved in Japan for the treatment of interstitial pneumonia (IP) in patients with polymyositis (PM) and dermatomyositis (DM). Postmarketing surveillance was initiated to examine long-term outcomes of immunosuppressive regimens containing tacrolimus in real-world settings. Methods. Observational, prospective, postmarketing surveillance is ongoing in 179 patients with PM/DM-associated IP initiating treatment with tacrolimus. We report interim findings after 2 years of follow-up. Cumulative overall survival was assessed using Kaplan-Meier analysis. Potential prognostic factors for mortality were assessed by univariate Cox proportional hazards analysis. Results. A total of 170 patients were included in this analysis. At the time of starting treatment with tacrolimus, almost all patients were receiving corticosteroids (98.8%), and cyclophosphamide was additionally used in 42 patients (24.7%). Forty-nine patients (28.8%) discontinued tacrolimus during follow-up, mainly due to loss to follow-up, patient death, and adverse events. Mean (SD) oral corticosteroid dose decreased from 32.4 (21.6) mg/day at baseline to 7.6 (4.2) mg/day at 2 years. Overall survival at 2 years was 90.3%; corresponding progression-free survival was 62.5%. Factors found to be associated with all-cause mortality included diagnosis of clinically amyopathic DM (hazard ratio [HR] 9.04, 95% CI 1.18-69.51 vs PM), ferritin level 500 to < 1500 ng/mL (HR 8.61, 95% CI 2.51-29.45 vs < 500 ng/mL), and presence of antimelanoma differentiation-associated gene 5 antibodies (HR 8.16, 95% CI 1.03–64.47 vs absence). Conclusion. Immunosuppressive regimens containing tacrolimus appear useful for the management of IP in patients with PM/DM. [ClinicalTrials.gov: NCT02159651]","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79391434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The Challenge of Addressing the Rheumatology Workforce Shortage 解决风湿病人力短缺的挑战
The Journal of rheumatology. Supplement Pub Date : 2022-04-15 DOI: 10.3899/jrheum.220300
E. Miloslavsky, Bethany Marston
{"title":"The Challenge of Addressing the Rheumatology Workforce Shortage","authors":"E. Miloslavsky, Bethany Marston","doi":"10.3899/jrheum.220300","DOIUrl":"https://doi.org/10.3899/jrheum.220300","url":null,"abstract":"The rheumatology workforce faces a deficit of physicians trained to provide high-quality care to patients with rheumatic diseases, and this deficit is projected to worsen over the next 10 to 15 years in many countries and regions around the world. Rheumatology workforce studies carried out in the US, Canada, and in Europe have revealed expected shortages driven by projections for increased demand; changes in demographics among providers, including increasing proportions of women and part-time clinicians as well as high levels of expected retirements; and geographic maldistribution of providers.1,2,3,4,5 In the last 2 years, practice changes caused by the coronavirus disease 2019 (COVID-19) pandemic have affected, and likely exacerbated, workforce limitations.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73880762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Post SARS-CoV-2 Vaccine Chilblains-like Lesions SARS-CoV-2疫苗后冻疮样病变
The Journal of rheumatology. Supplement Pub Date : 2022-04-15 DOI: 10.3899/jrheum.210996
R. Mungmunpuntipantip, V. Wiwanitkit
{"title":"Post SARS-CoV-2 Vaccine Chilblains-like Lesions","authors":"R. Mungmunpuntipantip, V. Wiwanitkit","doi":"10.3899/jrheum.210996","DOIUrl":"https://doi.org/10.3899/jrheum.210996","url":null,"abstract":"We would like to share ideas on the article, \"A Case of Chilblains-like Lesions Post SARS-CoV-2 Vaccine?\"1 Meara et al reported a female case and concluded, \"The chilblains-like lesions suggest that she had an antibody response from either 1 vaccine dose or a previous PCR-negative COVID-19 [coronavirus disease 2019] infection.\"1.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89327301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Childhood-onset Proliferative Lupus Nephritis in the 21st Century: A Call to Catch Up With the Evidence 21世纪儿童性增殖性狼疮性肾炎的治疗:追赶证据的呼唤
The Journal of rheumatology. Supplement Pub Date : 2022-04-01 DOI: 10.3899/jrheum.220196
D. Noone, E. Silverman
{"title":"Treatment of Childhood-onset Proliferative Lupus Nephritis in the 21st Century: A Call to Catch Up With the Evidence","authors":"D. Noone, E. Silverman","doi":"10.3899/jrheum.220196","DOIUrl":"https://doi.org/10.3899/jrheum.220196","url":null,"abstract":"Proliferative lupus nephritis (PLN) is associated with significant morbidity, mortality, and kidney failure, especially in childhood-onset PLN (cPLN). Therefore, it is important to treat it promptly and aggressively, while being cognizant of the risk-benefit ratio and side effects of therapies.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73105008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects. 基础科学1。银屑病关节炎治疗反应和关节损伤进展的生物标志物:2个行业- grappa项目的最新进展
The Journal of rheumatology. Supplement Pub Date : 2022-04-01 DOI: 10.3899/jrheum.211320
J. Waddington, Orla Coleman, P. Mease, V. Chandran, D. O'Sullivan, O. FitzGerald, S. Pennington
{"title":"Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects.","authors":"J. Waddington, Orla Coleman, P. Mease, V. Chandran, D. O'Sullivan, O. FitzGerald, S. Pennington","doi":"10.3899/jrheum.211320","DOIUrl":"https://doi.org/10.3899/jrheum.211320","url":null,"abstract":"The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has identified several priority areas for biomarker development, including biomarkers to predict at baseline which patients may progress to develop joint damage and whether a patient will respond to a specific targeted therapy. Two industry-GRAPPA projects were initiated in 2020 on these biomarker research areas: (1) the Pfizer-GRAPPA project, focused on biomarkers of treatment response to tofacitinib in the Oral Psoriatic Arthritis TriaL program; and (2) the Lilly-GRAPPA project, focused on biomarkers of damage in the ixekizumab SPIRIT-P1 randomized controlled trial. Preliminary results from these 2 projects were presented by the GRAPPA team, with both studies showing promising initial results. Data from these studies will be published when the studies have been completed. Large-scale validation studies are required and are under discussion.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81653546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Who Are We to Decide That the Unvaccinated Don’t Deserve Care? 我们凭什么决定未接种疫苗的人不值得照顾?
The Journal of rheumatology. Supplement Pub Date : 2022-04-01 DOI: 10.3899/jrheum.220110
C. Barnabe
{"title":"Who Are We to Decide That the Unvaccinated Don’t Deserve Care?","authors":"C. Barnabe","doi":"10.3899/jrheum.220110","DOIUrl":"https://doi.org/10.3899/jrheum.220110","url":null,"abstract":"","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83279570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
To Diagnose Enthesitis Clinically, Should the Entheses Be Put to Work? 临床诊断阑尾炎，是否应使用阑尾?
The Journal of rheumatology. Supplement Pub Date : 2022-04-01 DOI: 10.3899/jrheum.211052
J. Canoso, M. Saavedra, E. Naredo
{"title":"To Diagnose Enthesitis Clinically, Should the Entheses Be Put to Work?","authors":"J. Canoso, M. Saavedra, E. Naredo","doi":"10.3899/jrheum.211052","DOIUrl":"https://doi.org/10.3899/jrheum.211052","url":null,"abstract":"Clinicians use pain and tenderness elicited from local pressure at tendon, ligament, and capsular insertions to bone to identify enthesitis.1,2,3,4,5 In addition, certain entheses have an adjacent bursa or synovial space that, when distended by synovial fluid, adds certainty to a clinical diagnosis of enthesitis.6,7,8.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72519302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting. GRAPPA 2021年年会皮肤研究工作组报告。
The Journal of rheumatology. Supplement Pub Date : 2022-04-01 DOI: 10.3899/jrheum.211328
J. Yousif, J. Merola, L. Perez-Chada, C. Zagona-Prizio, A. Armstrong, A. Ogdie, Sangyoon Shin, A. Gottlieb
{"title":"Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting.","authors":"J. Yousif, J. Merola, L. Perez-Chada, C. Zagona-Prizio, A. Armstrong, A. Ogdie, Sangyoon Shin, A. Gottlieb","doi":"10.3899/jrheum.211328","DOIUrl":"https://doi.org/10.3899/jrheum.211328","url":null,"abstract":"The International Dermatology Outcome Measures (IDEOM) initiative presented an update on their progress related to instruments for psoriasis (PsO) and psoriatic arthritis (PsA) patient-centered outcome measures at the 2021 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The Treatment Satisfaction working group presented the development of a 7-item treatment satisfaction questionnaire specific for dermatological conditions. The group is beginning by assessing the validity and reliability of the instrument in PsO patient populations, with the ultimate goal of validating it for use in multiple dermatological diseases. The Musculoskeletal Symptoms working group discussed how implementation of a screening measurement tool in patients with PsO can help identify unknown diagnoses of PsA or prevent worsening of symptoms.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82029447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信